MERCK SCHEDULES PIVOTAL STUDY FOR ITS ORAL CORONA VIRUS TREATMENT IN SEPTEMBER

Highlights

• The experimental oral therapeutic is termed as MK-4482
• It is currently in phase two trials

Merck has scheduled very large pivotal studies as early as September. It is for its oral coronavirus treatment. It is in collaboration with Ridgeback Biotherapeutics. The statement came on Friday by a company executive.

Dr. Roger Perlmutter said that these studies are go....